Clinical trial
Individualized, Target-Driven Treatment Of Children With Idiopathic Short…
NCT00396097 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00396097 |
|---|---|
| Title | Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature |
| Official title | A Four Year Open Label Multi Center Randomized Two Arm Study Of Genotropin In Idiopathic Short Stature Patients: Comparing An Individualized, Target Driven Treatment Regimen To Standard Dosing Of Genotropin |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Short Stature |
| Intervention type | Drug |
| Interventions | Genotropin |
| Enrollment | 316 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Nov 6, 2006 |
| Last update posted | Apr 5, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: